July 16, 2024

Turning great science into impactful medicine: Lessons from Corey Goodman, Pioneer in Science and Venture Capital

Turning great science into impactful medicine: Lessons from Corey Goodman, Pioneer in Science and Venture Capital

Corey Goodman, Ph.D., is the managing partner of VenBio, a venture capital firm he cofounded in 2011. VenBio already has 7 FDA approved drugs on the market, saving and improving lives. Corey spent 25 years as Professor of Biology at Stanford...

Apple Podcasts podcast player badge
Spotify podcast player badge
Amazon Music podcast player badge
RSS Feed podcast player badge
Apple Podcasts podcast player iconSpotify podcast player iconAmazon Music podcast player iconRSS Feed podcast player icon

Corey Goodman, Ph.D., is the managing partner of VenBio, a venture capital firm he cofounded in 2011. VenBio already has 7 FDA approved drugs on the market, saving and improving lives.

Corey spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at U.C. Berkeley, where he was a HHMI Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute.

Corey co-founded seven biotechnology companies, and led one of them (Renovis) as President and CEO from a private to public company until its acquisition by Evotec. Two of the companies he co-founded have been acquired and three have done IPOs to date.  He then moved to Pfizer, where he was President of the Biotherapeutics and Bioinnovation Center and a member of the executive leadership team.

We talk about transformation of UC Berkeley as a startup powerhouse;  his entrepreneurial journey starting with the founding of Exelixis while being a faculty at UC Berkeley; role played by mentors and co-founders; lessons learned from founding startups that founders today could benefit from; changing careers at various stages of his life as he turned 50 and 60 (he recently turned 73); lessons from big pharma; experiences and lessons from partnerships and acquisitions by big pharma; and his experiences investing.

Show Notes: